Skip to main content
. 2020 Jan 19;23(3):316–324. doi: 10.1111/1756-185X.13780

Figure 4.

Figure 4

Distribution of disease activity by Week 52 DAS28(ESR) and rheumatoid factor in patients who were treated with CZP + MTX in Year 1 and entered the post‐treatment period (CZP + MTX→MTX; N = 108). CZP, certolizumab pegol; DAS28(ESR), disease activity score 28(erythrocyte sedimentation rate); MTX, methotrexate; RF, rheumatoid factor; SDAI, Simple Disease Activity Index